Quadrant Biosciences in the news

Developing solutions for important global health issues

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Our revolutionary  advancements in the early detection of autism spectrum disorder, Parkinson’s disease and mTBI,  through the application of the Clarifi™  epigenetic diagnostic platform, will have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. The first product to launch commercially from this platform will be our groundbreaking autism diagnostic aid, Clarifi ASD, which is slated for a Fall 2019 release.

Global Health 001

Be part of a study

Be part of a study

Autism research study

Children ages 18 months to 48 months with an autism diagnosis, developmental delays, or a suspicion of autism are eligible.

Parkinson’s Study

Help us learn how to better diagnose Parkinson’s Disease at an earlier stage.